Subscribe to Entrepreneur for $5
Subscribe

Rollins' (ROL) Q3 Earnings Miss Estimates, Increases Y/Y

Rollins' (ROL) third-quarter 2021 earnings and revenues increase year over year.

By
This story originally appeared on Zacks

Rollins, Inc. ROL reported mixed third-quarter 2021 results with earnings missing the Zacks Consensus Estimate but revenues beating the same.

- Zacks

Adjusted earnings of 19 cents per share missed the Zacks Consensus Estimate by 5% but increased 11.8% year over year. Revenues of $650.2 million beat the consensus mark by 1.3% and improved 11.4% year over year.

Rollins’ stock has gained 8.1% over the past six months, outperforming the 2.8% growth of the industry it belongs to.

Rollins, Inc. Price, Consensus and EPS Surprise Rollins, Inc. Price, Consensus and EPS Surprise

Rollins, Inc. price-consensus-eps-surprise-chart | Rollins, Inc. Quote

Other Quarterly Details

Organic revenues of $637.5 million increased 9.2% year over year. Organic revenues on a constant exchange rate were $637.1 million, increasing 9.2% year over year.

Adjusted EBITDA of $150.9 million increased 8.7% year over year. Adjusted EBITDA margin of 23.2% declined 60 basis points (bps) year over year.

Rollins exited the quarter with cash and cash equivalents balance of $117.7 million compared with the prior quarter’s $128.5 million. Long-term debt at the end of the quarter was $49.3 million compared with $69.3 million at the end of the prior quarter.

The company generated $79.7 million of cash from operating activities while capital expenditures were $6.8 million. Free cash flow was $72.9 million in the quarter.

Currently, Rollins carries a Zacks Rank #3 (Hold).

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Recent Performance of Some Other Business Services Companies

Equifax EFX reported better-than-expected third-quarter 2021 results. Adjusted earnings of $1.85 per share beat the Zacks Consensus Estimate by 7.6% but declined 1.1% on a year-over-year basis. Revenues of $1.22 billion outpaced the consensus estimate by 3.6% and improved 14.5% year over year.

IQVIA Holdings IQV reported impressive third-quarter 2021 results, with earnings per share of $2.17 beating the consensus mark by 1.9% and improving 33.1% on a year-over-year basis. Total revenues of $3.39 billion outpaced the consensus estimate by 1% and increased 21.7% year over year.

Omnicom OMC reported third-quarter 2021 adjusted earnings of $1.65 per share that beat the consensus mark by 20.4% and increased 36.4% year over year. Total revenues of $3.4 billion surpassed the consensus estimate by 0.6% and increased 7.1% year over year.



Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $2.4 trillion by 2028 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Recommendations from previous editions of this report have produced gains of +205%, +258% and +477%. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>



Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

 

Omnicom Group Inc. (OMC): Free Stock Analysis Report

 

Equifax, Inc. (EFX): Free Stock Analysis Report

 

Rollins, Inc. (ROL): Free Stock Analysis Report

 

IQVIA Holdings Inc. (IQV): Free Stock Analysis Report

 

To read this article on Zacks.com click here.

 

Zacks Investment Research